It is hoped these antibodies will eliminate the need for chemotherapy and radiotherapy by killing only “unwanted” cells and allowing more people who would otherwise be deemed unfit enough to receive a bone marrow transplant.
The antibodies are currently in pre-clinical trials with a phase I study pencilled in for early next year.
Hemogenyx said Monday’s deal boosts its chances of getting the antibodies into clinical trials and beyond.
Under the agreement, the global pharma company will provide Hemogenyx with free technical support, access to advanced methods of engineering antibodies as well as other things that should aid development.
In return, the pharma company will receive a research licence for anything jointly-developed under the agreement, as well as an option for an exclusive worldwide license to commercially exploit CDX antibodies or any variants, which will be jointly developed under the agreement.
Should the partner not exercise that option, Hemogenyx can license the jointly developed CDX antibodies or any variants.
“This agreement provides additional support for our development plans for CDX antibodies, and complements the work that we are already undertaking with our own resources,” said chief executive Vladislav Sandler.
“This close collaboration offers the potential for ongoing value-adding licensing arrangements with a major global pharmaceutical company with the benefit of their global reach and large-scale resources.”
Hemogenyx shares soared 24% to 4.72p.